Farris recently represented NanoVation Therapeutics, a Vancouver platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, on it’s multi-year partnership arrangement with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership combines NanoVation Therapeutics’ proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation. Under the terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to US$600 million in cash and milestone payments, as well as tiered royalties on future product sales.

NanoVation Therapeutics was represented by Farris Partner James P. Hatton, K.C. James is the partner responsible for the Technology Group at Farris and has more than 30 years experience assisting companies to exploit the value of their intellectual property assets.

For a full copy of the press release, click here.